Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 2;114(4):503–516. doi: 10.1093/jnci/djab106

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

PMC Copyright notice

Figure 5. — Forest plots of hazard ratios (HRs) for the predictive value of the consensus molecular subtypes (CMSs) for first-line systemic therapy in metastatic colorectal cancer. A) Progression-free survival for an irinotecan backbone vs control regimen. B) Overall survival for the addition of bevacizumab vs control regimen. C) Overall survival for the addition of bevacizumab vs cetuximab. ^aTotal number of patients, no information on the number of CMS4 patients. ^bKRAS wild-type population. ^c75.2% FOLFOX/24.8% FOLFIRI. ^dImmunohistochemistry classification: CMS2 and CMS3 depicted as CMS2. Bev = bevacizumab; Cap = capecitabine; CAPOX = capecitabine and oxaliplatin; Cet = cetuximab; CM = classification method; FOLFIRI = 5-fluorouracil, leucovorin, and irinotecan; FOLFOX = 5-fluorouracil, leucovorin, and oxaliplatin; mFOLFOX = modified FOLFOX; FOLFOXIRI, 5-fluorouracil, leucovorin, oxaliplatin and irinotecan; IRI = irinotecan; Mit = mitomycin; N = number of patients.